Company Description
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs.
Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF.
The company was formerly known as ShouTi Inc.
Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
| Country | United States |
| IPO Date | Feb 3, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 136 |
| CEO | Dr. Raymond C. Stevens Ph.D. |
Contact Details
Address: 611 Gateway Boulevard South San Francisco, California United States | |
| Website | https://structuretx.com |
Stock Details
| Ticker Symbol | GPCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001888886 |
| CUSIP Number | 86366E106 |
| ISIN Number | US86366E1064 |
| Employer ID | 98-1480821 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raymond C. Stevens Ph.D. | Chief Executive Officer & Director |
| Dr. Yingli Ma Ph.D. | Chief Technology Officer |
| Jun S. Yoon | Co- Founder, Chief Financial Officer & Secretary |
| Bob Gatmaitan | Senior Vice President of People |
| Dr. Fang Zhang Ph.D. | Executive Vice President & Head of Biology |
| Dr. Hui Lei Ph.D. | Senior Vice President of Chemistry |
| Dr. Xichen Lin Ph.D. | Chief Scientific Officer |
| Dr. Xinglong Jiang Ph.D. | Senior Vice President of Preclinical Development |
| Lani Ibarra | Senior Vice President of Clinical Development Operations |
| Tony Peng | Senior Vice President of Legal |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 20, 2024 | 4 | Filing |
| Sep 20, 2024 | 3 | Filing |